Clinical and Basic Researches Related to ZhenQi Buxue Oral Liquid in Treating Menstrual Disorders
- Conditions
- Menstrual Disorders
- Interventions
- Drug: ZhenQi BuXue KouFuYe
- Registration Number
- NCT05312190
- Lead Sponsor
- Peking Union Medical College Hospital
- Brief Summary
This study is a national multicenter prospective, randomized, controlled trial, which evaluates Zhenqi Buxue Oral Liquid，Progesterone Capsules and the addition of Zhenqi Buxue Oral Liquid to Progesterone Capsules in the treatment of menstrual disorders in adults women. One third of participanta will receive Zhenqi Buxue Oral Liquid, one third of participanta will receive Progesterone Capsules, and the another third will receive Zhenqi Buxue Oral Liquid and Progesterone Capsules in combination.
- Detailed Description
Menstrual disorders are one of the most common clinical symptoms in women. Since puberty, about 70% of women have experienced menstrual disorders, including early, delayed, shortened, prolonged, and more importantly oligomenorrhea, amenorrhea, and decreased menstrual flow.At present, the main method of western medicine for the treatment of menstrual disorders is hormone replacement therapy, but the incidence of adverse reactions is high, and the clinical effect is mediocre. Traditional Chinese medicine in my country mostly adopts holistic conditioning therapy for the treatment of irregular menstruation.
Zhenqi Buxue Oral Liquid consists of sheep placenta, pearl, red ginseng, wolfberry, astragalus, angelica, coix seed, ginger and jujube. The excipients are protein sugar and sodium benzoate. Nourishes qi and blood. It is suitable for dizziness, pale complexion, fatigue, lack of energy and lazy words caused by insufficient qi and blood.
This study will conduct a comprehensive and in-depth study on its treatment of mental and psychological stress and menstrual disorders with "oligomenorrhea, amenorrhea, amenorrhea and decreased menstrual flow" as the main manifestations. The molecular mechanism and clinical improvement, and the safety and adverse reactions of its use paln to be clarified.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 330
- Aged between 25 and 40 years old;
- Patients with oligomenorrhea or oligomenorrhea or menopause within three months (see Appendix 1: Diagnostic Criteria of Traditional Chinese and Western Medicine)
- Meet the clinical medication conditions for progesterone to regulate menstruation
- The research subjects were informed and voluntarily participated in this study, and signed the informed consent at the same time.
- Age <25 years or >40 years old, pregnant or breastfeeding women
- Ovarian dysfunction caused by local ovarian surgery, radiotherapy and chemotherapy for previous malignant tumors, taking hormones or immunosuppressive drugs;
- Combined with serious or unstable physical diseases that may affect the efficacy of drugs and the conduct of trials, including liver, kidney, gastrointestinal, cardiovascular, respiratory, endocrine, neurological, immune or blood system diseases, etc., mental patients .
- Those who were allergic to the drugs used in the trial or had serious adverse reactions in the past;
- Breast cancer or family history of breast cancer in first-degree relatives, irregular vaginal bleeding, uterine fibroids (≥3cm), endometriosis, atypical endometrial hyperplasia, endometrial cancer and other hormone-dependent reproduction Systemic diseases and other malignant tumors;
- Those with a history of thromboembolic disease or thrombosis;
- Participated in a clinical trial of another research drug within 3 months prior to inclusion in this study (the first interview);
- Those who have used related drugs in the past 3 months or have abused or depended on substances (alcohol or drugs) in the past 3 months; heavy smokers (smokers who smoke 20 or more cigarettes per day);
- Those who met the inclusion criteria, did not follow the doctor's advice, were unable to judge the curative effect or were unable to evaluate the curative effect due to incomplete data.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Zhenqi Buxue Oral Liquid ZhenQi BuXue KouFuYe Zhenqi Buxue Oral Liquid, 10 ml each time, 2 times a day for 3 menstrual cycles, orally Zhenqi Buxue Oral Liquid and Progesterone Capsules ZhenQi BuXue KouFuYe Zhenqi Buxue Oral Liquid was taken orally, 10 ml at a time, twice a day for 3 menstrual cycles + orally from the second half of menstrual cycle, Progesterone Capsules 200mg, once a day for 10 days for 3 menstrual cycles Zhenqi Buxue Oral Liquid and Progesterone Capsules Progesterone Capsules Zhenqi Buxue Oral Liquid was taken orally, 10 ml at a time, twice a day for 3 menstrual cycles + orally from the second half of menstrual cycle, Progesterone Capsules 200mg, once a day for 10 days for 3 menstrual cycles Progesterone Capsules Progesterone Capsules Progesterone Capsules 200mg, qd\*10 days\*3 menstrual cycles, orally
- Primary Outcome Measures
Name Time Method Menstrual improvement Within 3 months after the trial complete Menstrual improvement in monthly rates of amenorrhea
- Secondary Outcome Measures
Name Time Method Sex hormone levels Within 3 months after the trial complete mainly FSH, LH，E2 and AMH
AFC Within 3 months after the trial complete Changes in AFC in pelvic ultrasonography
SF-36 Within 3 months after the trial complete The change of the MOS item short from health survey
Trial Locations
- Locations (2)
Lei Li
🇨🇳Beijing, Beijing, China
Peking Union Medical College Hospital
🇨🇳Beijing, Beijing, China